Revolution Medicines, Inc. (FRA:42Z)

Germany flag Germany · Delayed Price · Currency is EUR
100.00
+1.00 (1.01%)
At close: Jan 23, 2026
156.41%
Market Cap15.78B +119.8%
Revenue (ttm)n/a
Net Income-819.04M
EPS-4.43
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume215
Open100.00
Previous Close99.00
Day's Range100.00 - 100.00
52-Week Range26.80 - 106.00
Betan/a
RSI47.07
Earnings DateFeb 26, 2026

About Revolution Medicines

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2014
Employees 809
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 42Z
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements